Biosynex SA (FR:ALBIO) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biosynex’s subsidiary, Chembio Diagnostics, has received a $1.5 million grant from the Bill & Melinda Gates Foundation to develop a rapid diagnostic test for congenital syphilis, a growing global health concern. The test aims to offer a quick, accurate, and affordable solution, particularly in low and middle-income regions, enhancing early diagnosis and treatment of syphilis in newborns and pregnant individuals.
For further insights into FR:ALBIO stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue